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Background: Acute leukemia in early age (EAL) is characterized by acquired genetic alterations such as MLL
rearrangements (MLL-r). The aim of this case-controlled study was to investigate whether single nucleotide
polymorphisms (SNPs) of IKZF1, ARID5B, and CEBPE could be related to the onset of EAL cases (<24 months-old at
diagnosis).
Methods: The SNPs (IKZF1 rs11978267, ARID5B rs10821936 and rs10994982, CEBPE rs2239633) were genotyped in
265 cases [169 acute lymphoblastic leukemia (ALL) and 96 acute myeloid leukaemia (AML)] and 505 controls by
Taqman allelic discrimination assay. Logistic regression was used to evaluate the association between SNPs of cases
and controls, adjusted on skin color and/or age. The risk was determined by calculating odds ratios (ORs) with 95%
confidence interval (CI).
Results: Children with the IKZF1 SNP had an increased risk of developing MLL-germline ALL in white children. The
heterozygous/mutant genotype in ARID5B rs10994982 significantly increased the risk for MLL-germline leukemia in
white and non-white children (OR 2.60, 95% CI: 1.09-6.18 and OR 3.55, 95% CI: 1.57-8.68, respectively). The heterozygous
genotype in ARID5B rs10821936 increased the risk for MLL-r leukemia in both white and non-white (OR 2.06, 95% CI:
1.12-3.79 and OR 2.36, 95% CI: 1.09-5.10, respectively). Furthermore, ARID5B rs10821936 conferred increased risk for
MLL-MLLT3 positive cases (OR 7.10, 95% CI:1.54-32.68). Our data do not show evidence that CEBPE rs2239633
confers increased genetic susceptibility to EAL.
Conclusions: IKZF1 and CEBPE variants seem to play a minor role in genetic susceptibility to EAL, while ARID5B
rs10821936 increased the risk of MLL-MLLT3. This result shows that genetic susceptibility could be associated with
the differences regarding MLL breakpoints and partner genes.
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Acute leukemia (AL) is one of the most common malignan-
cies of early childhood. Leukemias in infants (≤12 months)
(IL), even being rare, are recurrently studied because they
are associated with a high frequency of early death during
the first months of life. Despite advances in most other* Correspondence: mpombo@inca.gov.br
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article, unless otherwise stated.age groups, the prognosis of infants remains poor [1,2].
Therefore, understanding the contributing factors that
lead to the emergence of early age leukemia (EAL) repre-
sents a major opportunity of prevention. Contributing
events include chance, exposure to genotoxic substances,
and inherited genetic susceptibility.
Epidemiological and molecular studies have already
demonstrated that critical molecular lesions, such as the
frequently observed MLL gene rearrangements (MLL-r)
in IL, occur in utero in early hematopoietic precursors
[3,4]. Maternal exposures during pregnancy seem to beentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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to identify inherited susceptibility in childhood leukemia
(as a whole) have been made [8] and some studies have
already focused on EAL [9-13]. Common allelic variants in
IKZF1 (7p12.2), ARID5B (10q21.2), and CEBPE (14q11.2),
which are directly related to hematopoietic differentiation
and development, have been repeatedly and significantly
associated with childhood acute lymphoblastic leukemia
(ALL). Of interest, Xu et al. presented convincing evi-
dence for modifying effects of genetic ARID5B variants;
in particular these data consistently show a trend for in-
creasing allelic odds ratio as age decreased and the risk
varied substantially by ethnicity [14]. We have made
similar observations with age-dependent susceptibility
and leukemia emergence EAL [13]. However, the extent
to which germline variations contribute to the acquisi-
tion of somatic aberrations that define AL subtypes is
yet unknown.
Therefore, we genotyped common variants in IKZF1,
ARID5B, and CEBPE in a series of children enrolled in
the Brazilian Collaborative Study Group of Infant Acute
Leukemia (BCSGIAL) in order to evaluate the frequencies
of these inherited polymorphisms and determine their
associations by (i) age strata (infants versus children
aged between 13 and 24 months); (ii) MLL status and/
or type of MLL-r; and (iii) ethnic background. From our
data we conclude that distinct ARID5B rs10821936
polymorphism represents a novel risk factor to the ac-
quisition of somatic mutation as it increases the risk to
acquired MLL-r in EAL.Methods
Subjects
This study includes samples from 770 Brazilian children
(169 ALL, 96 AML and 505 controls) that were ascer-
tained from January, 2003 to December, 2012. They were
selected from the BCSGIAL, in which biological material
were available. BCSGIAL is a multicentric study, which
focuses on investigating the pathogenic mechanisms of
EAL in Brazil. Its characteristics and investigations have
been published elsewhere [6,15]. Briefly, it consists in a
hospital-based case–control study that aims to explore
the different risk factors associated with EAL. Cases have
been recruited from 15 institutions located throughout
all states of the country, but the Amazon. The studied
sample of enrolled participants included a ratio of 2 con-
trols per each EAL recruited case in each participating
center [6,11,13,15].
Cases and controls were age-matched and from the
same Brazilian regions. The exclusion criteria were chil-
dren with Down syndrome, myelodysplastic syndrome,
Fanconi anemia, Bloom’s syndrome, ataxia telangiectasia,
neurofibromatosis, and samples with bad quality DNA.Leukemia diagnosis
The diagnosis was first established through morphological
and immunophenotypic examinations of lymphoid and
myeloid cells according to standard criteria. Detection of
an MLL-r was performed by conventional cytogenetics,
reverse transcriptase polymerase chain reaction (PCR),
and/or by fluorescence in situ hybridisation (LSI MLL
Dual Color Break Apart Rearrangement Probe, Vysis
Inc., IL, USA) as previously described [15]. Long dis-
tance inverse PCR (LDI-PCR) was used to identify the
MLL translocation partner gene (TPG) and the respective
breakpoints. Briefly, 1 μg of genomic DNA was digested
and the resulting DNA fragments were self-ligated. This
re-ligated DNA was used for the subsequent LDI-PCR
analysis. PCR amplimers were purified from the gel and
subsequently sequenced to obtain chromosomal break-
point information [16].
Ethics
Data collection and laboratory procedures were evalu-
ated and approved by the Ethics Committee of all par-
ticipating hospitals. Data analysis was approved by the
Comitê de Ética em Pesquisa (CEP) -Instituto Nacional
de Câncer e Comitê Nacional de Ética em Pesquisa
(CONEP) (CEP #005/06 and #024/10; CONEP # 707/
2010). A written informed consent was obtained from
the mothers of the study subjects.
Genotyping
Genomic DNA was isolated from peripheral blood cells
or from buccal cells with the QIAamp DNA Blood Mini
Kit (Qiagen, USA) or with Oragene DNA technology
(Genotek, Ontario, Canada), respectively, and according
to the manufacturer’s instructions. For cases, remission
samples were used to isolate genomic DNA. Genotyping
of IKZF1 rs11978267, ARID5B rs10821936, ARID5B
rs10994982, and CEBPE rs2239633 was conducted by
Taqman allelic discrimination assay (Applied Biosys-
tems: Taqman SNP assays C_199413_10, C_26140184_10,
C_30824850_10, and C_335486_1). Genotype calls were
made upon visualization of allelic discrimination charts
in which the clusters were identified by comparison
with reference controls for each allele. To ensure quality
of genotyping, 10% of samples were analyzed randomly
in duplicates and concordance was absolute.
Statistical analysis
The expected gene polymorphism frequency was calcu-
lated using the Hardy-Weinberg law based on the allele
frequency in the control group. To compare the distri-
bution of genotypes between cases and controls the χ2-
test (two-sided) was used (or Fisher’s Exact Test when
expected values were less than five). P-values ≤0.05
were considered statistically significant. The disease
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subgroups of patients was determined by calculating
odds ratios (ORs) with 95% confidence interval (CI). A
multivariable logistic regression model (method enter)
was used to analyze associations between ARID5B variant
genotype and subtypes of MLL-r [i.e. genomic breakpoint
and TPG]. All statistical analyses were performed using
the Statistical Product and Services Solutions statistical
package, version 18.0 (SPSS Inc, Chicago, IL, USA).
Results
The call rate for IKZF1, ARID5B rs10821936 and
rs10994982, and CEBPE was respectively 247 of 265
(93.2%), 244 of 265 (92.1%), 246 of 265 (92.8%), and
251 of 265 (94.7%) in the investigated cases. The call
rate for each SNP was ≥94% in the control groups.
Control genotypes for all four SNPs loci were in
Hardy-Weinberg equilibrium (P > 0.05).
The demographic characteristics of cases and controls
are shown in Additional file 1: Table S1. There were no
statistical differences among cases and controls regarding
gender, ethnicity or children age range. The MLL status
was established for 149 ALL and 86 AML patients. The
analysis of genomic breakpoints by LDI-PCR within the
MLL breakpoint cluster region was performed in a subset
of 55MLL-r with available biological material and success-
fully determined in 41 cases.
The distribution of allele frequencies among controls
and cases within the major acute leukemia subtypes has
been evaluated and the results are shown in Additional
file 2: Table S2. The risk of developing the pro-B ALL
phenotype was increased for patients with the variant al-
lele of ARID5B rs10821936 (OR 2.54, 95% CI: 1.36-4.70).
Increased risks of developing c-ALL (CD10 positive)
have been observed for patients with variant alleles of
ARID5B rs10821936 (OR 2.63, 95% CI: 1.41-4.90) and
rs10994982 (OR 3.13, 95% CI: 1.24-7.95). Among pa-
tients with AML, an increased risk has been observed
for those patients with the homozygous variant of
ARID5B rs10821936 (OR 2.39, 95% CI: 1.10-5.17).
The distributions of allele frequencies in controls and
cases and the risk association between genetic variants
and acute leukemia further stratified by skin color and by
MLL status are displayed in Additional file 3: Table S3. In
overall cases, white and non-white children presented
similar risk associations. The heterozygous genotype in
ARID5B rs10821936 increased the risk for MLL-r
leukemia in both white and non-white (OR 2.06, 95%
CI: 1.12-3.79 and OR 2.36, 95% CI: 1.09-5.10, respect-
ively). The mutant genotype in ARID5B SNP rs10821936
significantly increased the risk for MLL-germline leukemia
in white and non-white children (OR 2.69, 95% CI: 1.28-
5.66 and OR 3.69, 95% CI: 1.57-8.68, respectively). The
heterozygous/mutant genotype in the other ARID5Brs10994982 also significantly increased the risk for MLL-
germline leukemia in white and non-white children (OR
2.60, 95% CI: 1.09-6.18 and OR 3.55, 95% CI: 1.57-8.68,
respectively).
When comparing the ALL cases by age strata (infants
versus children aged between 13 and 24 months), white
children with ALL of both age groups presented with an
increased risk for MLL-germline leukemia associated
with the heterozygous/mutant genotypes IKZF1 (OR
5.57, 95% CI: 1.39-22.24 and OR 2.58, 95% CI: 1.02-6.51,
respectively). The heterozygous genotype in ARID5B
rs10821936 increased the risk for MLL-r ALL in both
white and non-white infants (OR 2.19, 95% CI: 1.07-4.49
and OR 3.82, 95% CI: 1.21-12.12, respectively), while for
children aged between 13–24 months the mutant geno-
type significantly increased the risk for ALL in white
children, regardless the MLL status (OR 7.11, 95% CI:
2.07-24.45 for MLL-germline; OR 7.91, 95% CI: 1.47-42.46
for MLL-r) (Additional file 3: Table S3).
In AML, the only increased risk association was ob-
served among non-white MLL-r cases with the ARID5B
rs10821936 mutant genotype (OR 4.82, 95% CI: 1.50-
15.50), while the CEBPE variant allele was negatively
associated with MLL-germline AML (OR 0.22, 95% CI:
0.07-0.72) (Additional file 3: Table S3).
The SNPs risk associations between acute leukemia
and MLL status are also shown after statistical adjustment
on age and on skin color (Additional file 4: Table S4). The
results corroborate with those obtained after stratification,
showing that IKZF1 and ARID5B rs10994982 variant
alleles play a role in the susceptibility to MLL-germline
leukemia while ARID5B rs10821936 confers increased risk
to bothMLL-germline and MLL-r leukemia.
Because the variant ARID5B rs10821936 allele was
remarkably associated with an increased risk of MLL-r
acute leukemia, we tested whether this risk allele was
associated to a specific MLL TPG or to any of the
frequent MLL breakpoint regions. The risk association
between ARID5B rs10821936 and MLL-r acute leukemia
according to the TPGs and MLL breakpoint regions com-
pared with controls is shown in Table 1. The individuals
with heterozygous/mutant genotype had a higher risk of
developing MLL-AFF1 positive leukemia (OR 2.79, 95%
CI: 1.27-6.11) and even higher odds of MLL-MLLT3
positive leukemia (OR 7.10, 95% CI: 1.54-32.68). More-
over, this increased risk magnitude was also observed
for individuals with MLL breakpoints non-located in
MLL intron 11 (OR 10.25, 95% CI: 2.24-46.81). A multi-
variate analysis has been performed to address whether
the MLLT3 TPG and the MLL breakpoint region (exon
9-intron 10) were variables dependent on each other.
The results showed that the susceptibility risk of having
the MLL breakpoint localized outside of MLL intron 11
[(OR 0.88, 95% CI: 0.34–2.30), P = 0.79] and the MLLT3
Table 1 The risk associations between ARID5B rs10821936 genotype and MLL translocation partner genes or MLL
breakpoint region, Brazil, 2003-2013







A (n = 15) and
B (n = 8)
C (n = 18)
n n OR (95% CI)b,c n OR (95% CI)b,c n OR (95% CI)b,c n OR (95% CI)b,c n OR (95% CI)b,c
ARID5B
rs10821936
TT 200 11 1.00 6 1.00 2 1.00 2 1.00 5 1.00
TC 205 27 3.26 (1.42-7.49) 11 2.82 (0.89-8.93) 12 8.62 (1.77-41.94) 17 12.76 (2.66-61.23) 12 3.45 (1.08-11.05)
CC 68 6 1.95 (0.62-6.11) 4 2.12 (0.52-8.63) 3 5.18 (0.79-34.02) 4 6.65 (1.08-41.15) 1 0.85 (0.09-8.25)
TC + CC 273 33 2.79 (1.27-6.11) 15 2.53 (0.89-7.22) 15 7.10 (1.54-32.68) 22 10.25 (2.24-46.81) 14 2.72 (0.88-8.43)
n, number of individuals; OR, odds ratio; CI, confidence intervals; aThe MLL breakpoint region was subdivided according to Meyer et al., 201332 as follows: (A) Exon
9-Intron 9, (B) Exon 10-Intron 10, (C) Intron 11; bAdjusted on age; cAdjusted on skin color.
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cross-dependent.
We further tested the effect of cumulative variant al-
leles of IKZF1, ARID5B and CEBPE in the risk suscepti-
bility to EAL (Additional file 5: Table S5). Patients
harboring 6–8 variant alleles had significant increased
risk to develop ALL older than 12 months-old (OR 1.34,
95% CI: 1.09-1.66) or MLL-germline leukemia (OR 1.33,
95% CI: 1.06-1.67). However, we could not observe a
trend for increasing ORs as the number of risk alleles
increased.Discussion
The molecular epidemiological approach in several gen-
etic studies has raised the concept that most, if not all,
childhood leukemia cases originate in utero [4]. Previ-
ous evidences suggested that the causality factors are
likely to be multiple and leukemia subtype-specific,
combining both genetic susceptibility and environmen-
tal exposures [17]. Moreover, whether and how the
inherited gene variants contribute to the acquisition of
the in utero-acquired somatic alterations frequently
found in EAL must be explored.
In this case–control study, we genotyped known sus-
ceptibility loci (IKZF1, ARID5B, and CEBPE) in a series
of children enrolled in the BCSGIAL. We observed an
increased magnitude of ALL risk for children with SNPs
in IKZF1 and ARID5B. This is expected from the previ-
ous genome wide association studies (GWAS) that have
been performed in childhood ALL (peak incidence 2–
5 years-old) [18,19]. Our data do not show evidence that
CEBPE rs2239633 confers increased genetic susceptibil-
ity to EAL, in agreement with previous data in IL [12].
In a recent GWAS, CEBPE SNPs were strongly related
to ALL risk in European Americans, with variable effects
in non-European populations [14]. This result could ex-
plain the lack of association in our population.IKZF1 rs11978267 was associated with the increased
risk of MLL-germline ALL in both infants and older
children consistent with results found in previous set-
tings of childhood ALL. Different from ours, the only
previous study that has also addressed involvement of
IKZF1 polymorphism in AML has found a contribution
of rs11978267 to susceptibility in infant AML overall, ir-
respective of MLL-r [12]. However, because of the differ-
ences in number of cases and ethnicity among studied
populations, it is difficult to draw conclusions from this
comparison. Therefore, further studies focusing on AML
will be necessary to verify the IKZF1 susceptibility role
in EAL. As this is an extremely rare disease, pooling
studies would be of great interest.
ARID5B gene variants have been systematically shown
to increase the risk of childhood ALL in various popula-
tions [14,18-23]. Most of these studies showed that this
risk was associated to B-cell precursor ALL, and some of
them could distinguish B-hyperdiploid ALL from other
subtypes [18,19,24]. This association with B-hyperdiploid
ALL has not been reproduced in all studies [25]. Overall,
the ARID5B gene variants were strongly associated with
the risk of EAL in this Brazilian series. This gene en-
codes a member of the AT-rich interaction domain
(ARID) family of DNA binding proteins. The encoded
protein forms a histone H3K9me2 demethylase complex
together with PHD finger protein 2 to regulate the tran-
scription of target genes involved in adipogenesis and
liver development [26]. An increased risk of ARID5B
variants in AML had not been reported previously. The
gene expression level of ARID5B is up-regulated in two
different AML subtypes (acute megakaryoblastic and
promyelocytic leukemia) [27,28]. Acute megakaryoblastic
leukemia is more frequent in EAL AML opposite to pro-
myelocytic leukemia [29,30]. Therefore, it is conceivable
that ARID5B contributes to susceptibly to EAL AML, and
an ongoing case–control study is currently underway to
answer this question [31].
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the risk in MLL germline children, in agreement with ob-
servations in childhood [18,19] and IL [12]. We observed
a major and wider spectrum of risk increase for ARID5B
rs10821936. This is consistent with previously mentioned
studies, as this specific SNP has been strongly associated
with risk across several populations and leukemia sub-
groups. In our study, the rs10821936 increased the risk for
both MLL wild-type and MLL-r ALL and MLL-r AML pa-
tients. One of the most significant findings from this study
is that ARID5B rs10821936 not only differed between EAL
and control groups but also distinguished MLL-MLLT3
positive leukemias from other MLL-r. Interestingly, a
strong association could be observed both by analyzing
the TPG (MLLT3) and the breakpoint location of MLL
(mainly intron 9), and the multivariate model confirmed
that these parameters were dependent on each other. Re-
cently, the MLL recombinome analysis pointed out differ-
ent tendencies concerning the breakpoints localization
when it was analyzed breakpoint distributions together
with TPGs [32]. For that study, the MLL breakpoint
cluster region was subdivided into 3 sub regions (A,
exon 9 - intron 9; B, exon 10 - intron 10; C, exon 11 -
intron 12). The observed ‘mean breakpoint frequencies’
for these 3 regions in South America (dataset includes
our Brazilian samples) was A = 31.9%, B = 21.7%, and
C = 43.5%. However, when separating by MLLT3 TPG
and restricted to the infants subgroup, the MBPF was
A = 41.8%, B = 13.3%, and C = 42.9%, while in pediatric
and adults these ‘mean breakpoint frequencies’ were:
35.7%, 18.8%, 43.8% and 34.2%, 7.59%, 57.0%, respectively.
Therefore, recombination affecting MLLT3 displayed a
tendency forMLL intron 9 breaks in IL. Together, all these
data are concordant with our finding that increased risk
susceptibility in infants is associated with MLL-MLLT3 re-
arrangement. Although future studies will be necessary to
confirm this finding and to understand the specific role of
this SNP in the pathogenesis, the availability of such rare
epidemiological set of cases prompted us to suggest an
association between inherited gene variants and specific
somatic aberrations in the pathogenesis of MLL-r EAL.
There are limitations in this present analysis. First, the
small number of cases after some subsets stratification
raises concern with regards to statistical power. However,
given the rarity of this disease, one should consider that the
consistency of the associations observed, and the concord-
ance with previously published data indicate good validity
and sensitivity of our study. Second, we had missing geno-
typing calls in some cases and controls that precluded us to
have all samples screened uniformly. However, an accept-
able call rate has been achieved in either cases or controls
and the frequencies obtained did not present any deviation.
We can also mention some study strengths. As repli-
cation of GWAS is highly desirable, this is an importantcontribution of the present Brazilian work, especially
because the studies have been so far concentrated to
European and American populations. For example, val-
idation sequencing of this ARID5B genomic region has
been requested in order to reveal the exact nature of the
differences previously observed. Moreover, this report
focus on EAL and particularly those harboring MLL-r,
and in this context, this study is innovative.
Conclusions
In summary, we have shown that IKZF1 and CEBPE
studied genetic variants seem to play a minor role in
susceptibility to EAL, while ARID5B seems to contribute
to the multifactorial causes of this disease, even increas-
ing the risk of specific acquired somatic abnormalities
such as the MLL-r recurrently seen in IL. This know-
ledge sheds new light onto the complex interactions that
exist between environmental factors, inherited polymor-
phisms, and somatic alterations in leukemogenesis. While
improvements on successful therapy have being hard to
achieve within very young children, prevention is a major
need and, therefore, the clarification of etiology should be
tirelessly pursued.
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